Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
January 9th, 2019
9.6K views
Here, we present an ablate-and-resect prospective study to evaluate the feasibility, safety, and accuracy of intraoperative high-intensity focused ultrasound ablation in patients undergoing hepatectomy for liver metastases.
Overview
This study evaluates the feasibility, safety, and accuracy of intraoperative high-intensity focused ultrasound (HIFU) ablation in patients undergoing hepatectomy for liver metastases. The technique aims to provide a new therapeutic option for patients with unresectable liver metastases.
Key Study Components
Area of Science
- Neuroscience
- Medical Devices
- Surgical Techniques
Background
- High-intensity focused ultrasound (HIFU) is a non-invasive therapeutic option.
- It allows for precise targeting of liver lesions.
- The technique is guided by ultrasound imaging.
- Previous studies have shown promise in treating liver metastases.
Purpose of Study
- To assess the safety and efficacy of HIFU during liver surgery.
- To determine the accuracy of HIFU in ablating liver metastases.
- To explore the potential for HIFU to improve surgical outcomes.
Methods Used
- Preparation of the HIFU device and surgical site.
- Use of ultrasound imaging to guide HIFU ablation.
- Monitoring temperature rise during ablation to ensure safety.
- Post-surgical analysis of ablation effectiveness and tissue samples.
Main Results
- A total of 12 HIFU ablations were successfully created in six patients.
- Deep HIFU lesions were placed at a mean depth of approximately 10 mm.
- Sharp delimitation between treated and untreated liver tissue was observed.
- Initial results support further clinical development of HIFU for liver metastases.
Conclusions
- HIFU is a promising technique for liver ablation during surgery.
- It demonstrates safety and precision in targeting liver metastases.
- Further studies are warranted to confirm efficacy in larger cohorts.
Frequently Asked Questions
What is HIFU?
HIFU stands for high-intensity focused ultrasound, a non-invasive treatment that uses ultrasound waves to ablate tissue.
How does HIFU work?
HIFU works by focusing ultrasound energy on a specific area, raising the temperature to destroy targeted tissues.
What are the advantages of using HIFU?
HIFU offers precise targeting, minimal damage to surrounding tissues, and can be guided by real-time imaging.
Is HIFU safe?
Initial studies indicate that HIFU is safe when used under controlled conditions during surgery.
What are the next steps for HIFU research?
Future studies will focus on larger patient groups and the effectiveness of HIFU on smaller metastases.
Executive Industry Relevance
Intraoperative high-intensity focused ultrasound (HIFU) offers a non-invasive ablation strategy for liver metastases, addressing limitations of current thermal therapies such as probe trauma and lack of real-time monitoring. By enabling rapid, precise tissue ablation under ultrasound guidance, HIFU supports mechanistic de-risking in preclinical and early clinical development of liver-directed therapies. Its integration into surgical workflows provides a platform for evaluating therapeutic precision and safety margins in disease-relevant models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by creating controlled ablation zones in liver parenchyma to study tissue response and cell death mechanisms.
- Operational Value: Provides reproducible ablation volumes (approximately 7.5 cm³) with 1–2 mm precision, supporting consistent experimental conditions across studies.
Screening & Assay Development
- Scientific Value: Generates quantifiable ablation metrics (dimensions, volume, sharp demarcation) that serve as pharmacodynamic readouts for energy-based interventions.
- Operational Value: Uses integrated ultrasound imaging for real-time monitoring and post-ablation measurement, enabling standardized assessment across operators and sessions.
Translational & Preclinical Research
- Scientific Value: Supports disease-relevant system modeling by allowing ablation in metastatic liver tissue, facilitating study of tumor microenvironment changes post-treatment.
- Operational Value: Demonstrates safety and feasibility in resected liver tissue, enabling risk-adjusted advancement to in vivo studies without compromising subject safety.
Pipeline & Workflow Integration
Positioned at the discovery-to-preclinical interface, intraoperative HIFU supports hypothesis testing in liver metastasis models and enables standardized ablation for downstream analytical workflows.
- Discovery Biology: Facilitates pathway clarification by creating defined lesions to study inflammatory, fibrotic, or regenerative responses in liver tissue.
- Screening: Delivers quantitative ablation outputs (size, shape, demarcation sharpness) that allow comparison of energy delivery parameters and tissue effects.
- Analytics: Provides measurable traces (hyperechoic/hypoechoic zones, 200 µm halo) for histopathological correlation and imaging validation.
- Translational Research: Enables continuity from ex vivo ablation studies to preclinical models by maintaining consistent lesion characteristics across platforms.
- Enterprise Reuse: Represents a reusable platform for ablation standardization, reducing variability in preclinical efficacy and safety assessments.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence through precise, reproducible ablation with sharp tissue demarcation and minimal collateral damage.
- Operational Value: Achieves ablation in 40 seconds with 1–2 mm accuracy, supporting high-throughput sample processing and workflow integration.
- Strategic Value: Reduces biological de-risking uncertainty by enabling controlled lesion generation for mechanism-of-action studies.
- Portfolio Impact: Informs go/no-go decisions by providing reliable ablation models for evaluating liver-directed therapeutic candidates.
Implementation Considerations
- Requires expertise in surgical device handling, sterile field maintenance, and ultrasound-guided ablation techniques.
- Depends on specialized HIFU probe with toroidal transducer, sterile coupling envelope, and integrated ultrasound imaging for real-time guidance.
- Necessitates cross-functional coordination between surgical, imaging, and pathology teams for ablation execution and tissue analysis.
- Involves adaptation considerations for varying liver parenchyma characteristics, including vascularity and fibrosis, which may affect ultrasound propagation.
- Limited to ex vivo or resected tissue applications in current feasibility studies, constraining direct use in intact organ models without further validation.
Biopharma FAQs
Why does real-time ultrasound guidance matter for HIFU ablation accuracy?
Real-time ultrasound guidance enables precise positioning of the HIFU focal zone on the liver surface, allowing operators to align the ablation target with anatomical landmarks. This guidance ensures the ablation occurs at the intended location, as demonstrated by the sharp delimitation between treated and untreated tissue. Accurate targeting is critical for reproducible lesion generation in preclinical and translational studies.
How does isolating the ablation zone as an independent variable support mechanistic studies?
By creating controlled ablation zones in healthy liver tissue scheduled for resection, the study isolates the effect of HIFU energy from confounding variables such as tumor biology or systemic treatment. This enables researchers to study the direct tissue response to thermal ablation, including cell death patterns and inflammatory reactions. Isolating the independent variable supports mechanistic de-risking by clarifying the biological consequences of the intervention itself.
What quantitative measurements of ablation dimensions enable comparative analysis across studies?
The study measures ablation dimensions along two orthogonal planes using the integrated ultrasound probe, reporting average sizes of 27.5 x 21.0 mm² and volumes of approximately 7.5 cm³. These quantitative outputs allow standardized comparison of ablation efficiency across different device settings, tissue types, or experimental conditions. Such metrics are essential for establishing dose-response relationships in preclinical screening assays.
Why do replication requirements (multiple ablations per patient) matter for cross-functional team confidence?
Creating multiple HIFU ablations per patient (30 ablations in 15 patients) demonstrates reproducibility and consistency of the technique across different liver regions and operators. This replication builds confidence in the reliability of the ablation model for use in discovery and screening workflows. Consistent performance supports standardization efforts across preclinical labs and translational research teams.
What statistical analysis of ablation precision is required before adopting HIFU in preclinical workflows?
The study reports a precision of 1–2 mm in ablation placement, which must be evaluated for statistical significance and variance to assess suitability for preclinical applications. Understanding the distribution of ablation accuracy enables teams to define acceptable error margins for study design and power calculations. This analysis is necessary to determine whether the method meets the reproducibility thresholds required for reliable comparative experiments.
